<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616367</url>
  </required_header>
  <id_info>
    <org_study_id>1503M66201</org_study_id>
    <nct_id>NCT02616367</nct_id>
  </id_info>
  <brief_title>Comparison of Comparison of Ropivacaine and Liposomal Bupivacaine for Total Knee Arthroplasty</brief_title>
  <official_title>Comparison Between Ropivacaine and Liposomal Bupivacaine Periarticular Injections for Pain Relief After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized prospective outcomes study comparing two groups of patients. One group&#xD;
      will receive liposomal bupivacaine for a periarticular injection. The other will receive&#xD;
      ropivacaine for periarticular injection for pain relief after Total Knee Arthroplasty. the&#xD;
      primary objective of this study is to determine if liposomal bupivacaine provides superior&#xD;
      pain control (decreased maximal pain scores within the first 72 hours post surgery) when&#xD;
      compared to ropivacaine when injected in a periarticular injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care at our institution for pain relief in Total Knee Arthroplasty is&#xD;
      ropivacaine injectate into the knee for acute postoperative pain relief. This provides pain&#xD;
      relief for a duration of 6-18 hours after surgery. All patients in this study will also&#xD;
      receive multimodal analgesia following surgery in both arms of the study. This will be the&#xD;
      first study to prospectively analyze these two regimens.&#xD;
&#xD;
      Study group 1 (ropivacaine arm) consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL&#xD;
      normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine) Study group 2 will consist of&#xD;
      100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL&#xD;
      ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL&#xD;
      liposomal bupivacaine 30 mL normal saline). The periarticular injection will occur at the end&#xD;
      of the procedure. Adequate analgesia will be defined as &lt; 3 VAS at rest and if VAS is greater&#xD;
      that 3 adjustments in oral or intravenous pain medications. Postoperatively the study team&#xD;
      will evaluate for any signs of complications. Pain scores and opioid usage will be recorded&#xD;
      daily while the subject is in the hospital. A quality of recovery survey will be completed at&#xD;
      72 hours post injection. All subjects will be contacted by phone at day 14 to determine if&#xD;
      there have been any adverse events and report their pain level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never initiated&#xD;
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain control measure on pain scale of 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>to determine if liposomal bupivacaine provides superior pain control (decreased maximal pain control (decreased maximal pain scores) when compared to ropivacaine when injected in a periarticular injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>decreased maximal pain on pain scale of 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>Liposomal bupivacaine via a periarticular injection will result in a decreased maximal pain and improved quality of recovery when compared to ropivacaine when injected in a periarticular injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthroplasty</condition>
  <condition>Replacement</condition>
  <condition>Knee</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine Periarticular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine Periarticular Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine Periarticular injection</intervention_name>
    <description>Liposomal bupivacaine used for a periarticular injection in the knee</description>
    <arm_group_label>liposomal bupivacaine Periarticular injection</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Periarticular Injection</intervention_name>
    <description>Periarticular Injection for the knee with ropivacaine</description>
    <arm_group_label>Ropivacaine Periarticular Injection</arm_group_label>
    <other_name>Norapin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients undergoing primary total knee arthroplasty surgery 18-80.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient on chronic anticoagulation&#xD;
&#xD;
          -  Allergy to local anesthetics, nsaids, or opioids&#xD;
&#xD;
          -  Patients who remain intubated for one week after surgery or who are unable to provide&#xD;
             information as to their feelings of pain post-operatively for the first week post-&#xD;
             operatively&#xD;
&#xD;
          -  Daily use of opioid for more than three weeks&#xD;
&#xD;
          -  Lack of patient cooperation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto D Blanco</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

